Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it ...

Biogen’s treatment for Alzheimer’s was ... would ‘realign resources’ for its Alzheimer’s portfolio and stop selling Aduhelm. The highly anticipated launch, along with blockbuster ...

In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...

A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...

In the fourth quarter of 2021, for example, Aduhelm could only muster $1 million in sales. Since then, prospects for the biologic didn’t appreciably improve. The drug’s manufacturer Biogen ...

Investors knocked Biogen stock down by more than 10% early Wednesday after the US Centers for Medicare and Medicaid Services set a limit on its coverage of Aduhelm, the company's drug to treat ...

with management confident in overcoming any major hurdles based on their experience from the Aduhelm launch. Furthermore, Biogen’s proactive approach to building out infrastructure to support ...

Biogen, Inc. is a biopharmaceutical company ... SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

Shares of Biogen Inc. BIIB inched 0.49% higher to $185.68 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 and ...